Cantor Fitzgerald Initiates Pernix Therapeutics At Buy

Analysts at Cantor Fitzgerald initiated coverage on Pernix Therapeutics Holdings, Inc. PTX with a Buy rating. The target price for Pernix Therapeutics is set to $11. Pernix Therapeutics shares have gained 172.33% over the past 52 weeks, while the S&P 500 index has surged 12.47% in the same period. Pernix Therapeutics' shares jumped 1.59% to $8.30 in after-hours trading.